2022 has (so far) been brutal for MedTechs – down c.27% in market value terms vs. c.10% correction for the AV universe stocks. This is a stark underperformance for…
2022 has (so far) been brutal for MedTechs – down c.27% in market value terms vs. c.10% correction for the AV universe stocks. This is a stark underperformance for…